[at noodls] – South San Francisco, CA – March 11, 2013 Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update … moreView todays social media effects on CYTKView the latest stocks trending across Twitter. Click to view dashboardSee who Cytokinetics is hiring next, click here to view […]
[at noodls] – South San Francisco, CA – February 22, 2013 Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that members of its management team are scheduled to participate at the following healthcare conferences: … moreView todays social media effects on CYTKView the latest stocks trending across Twitter. Click to view dashboardSee who Cytokinetics is hiring next, click here to view […]
[at noodls] – South San Francisco, CA – February 12, 2013 Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the opening to enrollment of a Phase II clinical trial of oral formulations of omecamtiv mecarbil. … moreView todays social media effects on CYTKView the latest stocks trending across Twitter. Click to view dashboardSee who Cytokinetics is hiring next, click here to view […]
[at noodls] – Steve Dow Will Not Stand for Re-Election at the Annual Meeting of Shareholders; B. Lynne Parshall Has Been Appointed to the Company’s Board South San Francisco, CA – February 8, 2013 Cytokinetics, Incorporated … moreView todays social media effects on CYTKView the latest stocks trending across Twitter. Click to view dashboardSee who Cytokinetics is hiring next, click […]
[ACN Newswire] – Company Recaps Significant Milestones in Ongoing Phase IIb Clinical Trials Expected to Generate Results in 2013 South San Francisco, CA, Feb 6, 2013 – (ACN Newswire) – Cytokinetics, Incorporated (Nasdaq: … moreView todays social media effects on CYTKView the latest stocks trending across Twitter. Click to view dashboardSee who Cytokinetics is hiring next, click here to view […]
[at noodls] – South San Francisco, CA – January 29, 2013 Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report fourth quarter results on Tuesday, February 5, 2013 at 4:00 PM Eastern … moreView todays social media effects on CYTKView the latest stocks trending across Twitter. Click to view dashboardSee who Cytokinetics is hiring next, click here […]
[at noodls] – Cytokinetics Highlights Progress of Activities Directed to Muscle Biology at Today’s Research & Development Day Two First-In-Class Programs Advancing in Phase IIb Clinical Trials; Company Convenes Panel … moreView todays social media effects on CYTKView the latest stocks trending across Twitter. Click to view dashboardSee who Cytokinetics is hiring next, click here to view […]
[at noodls] – Pharmacokinetics of Tirasemtiv Are Dose Proportional; Positive and Concentration Dependent Effects Were Observed on Multiple Functional Measures South San Francisco, CA – December 7, 2012 Cytokinetics, … moreView todays social media effects on CYTKView the latest stocks trending across Twitter. Click to view dashboardSee who Cytokinetics is hiring next, click here to view […]
[at noodls] – Independent Data Monitoring Committee Recommends Progression in Ongoing Phase IIb Clinical Trial of Intravenous Form of Omecamtiv Mecarbil in Patients with Acute Heart Failure South San Francisco, CA – … moreView todays social media effects on CYTKView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – Myasthenia Gravis Is the Third Disease in which Single Doses of Tirasemtiv Have Produced Potentially Clinically Meaningful Pharmacodynamic Effects in Phase II Trials South San Francisco, CA – November … moreView todays social media effects on CYTKView the latest stocks trending across Twitter. Click to view dashboard […]
